EyePoint announces interim masked safety data for EYP-1901

EyePoint Pharmaceuticals announced positive interim masked safety data for its lead product candidate EYP-1901 from the Company’s ongoing Phase 2 PAVIA trial evaluating EYP-1901 as a potential nine-month treatment for moderately-severe to severe non-proliferative diabetic retinopathy and DAVIO 2 trial as a potential six-month sustained delivery maintenance treatment for wet age-related macular degeneration. All treatment arms in the PAVIA trial have reached at least 3-months post-dosing follow-up as of September 1, 2023. Approximately 170 patients have received EYP-1901 with a minimum of three months of follow-up post injection from the ongoing Phase 2 PAVIA and DAVIO 2 clinical trials and the completed DAVIO 1 trial with no reported drug-related ocular severe adverse events and no reported drug-related systemic SAEs. In the PAVIA clinical trial, there have been no reported drug-related ocular SAEs and no reported drug-related systemic SAEs. There were two ocular SAEs deemed unrelated to EYP-1901 by investigators: Hemorrhagic posterior vitreous detachment in a study eye eight weeks after dosing; Macular edema leading to vision loss in the non-study fellow eye